Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regulus Therapeutics Inc. - Common Stock (NQ:RGLS)

7.830 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regulus Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
Via Benzinga
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead
Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a... 
Via Stocktwits
Topics Stocks
Exposures US Equities
Wednesday's session: top gainers and losers
Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
Top stock movements in today's session.
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Wednesday's session: gap up and gap down stocks
The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
Novartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone; deal set to close in H2 2025. 
Via Benzinga
These stocks that are showing activity before the opening bell on Wednesday.
Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
S&P 500 Falls 2%; Caterpillar Reports Downbeat Q1 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis
According to the terms of the deal, Novartis, through a subsidiary, will initiate a tender offer to acquire all of Regulus' outstanding shares for an initial price of $7.00 per share or $800 million. 
Via Stocktwits
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Top movers analysis one hour before the close of the markets on 2025-04-28: top gainers and losers in today's session.
Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
These stocks are moving in today's session
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
These stocks have an unusual volume in today's session
Volume analysis on 2025-04-01: stocks with an unusual volume in today's session. 
Via Chartmill
Top stock movements in today's session.
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease
Regulus Therapeutics' Phase 1b study shows farabursen 300 mg slowed kidney volume growth in ADPKD patients with a favorable safety profile. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Traders are paying attention to the gapping stocks in Tuesday's session.
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
Here are the top movers in Wednesday's session.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q2 2024
RGLS stock results show that Regulus Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
What's Going On With Regulus Therapeutics Stock Monday?
Regulus Therapeutics announced positive results from its study related to the treatment of autosomal dominant polycystic kidney disease (AKPD). 
Via Benzinga
RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q1 2024
RGLS stock results show that Regulus Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028
Finding good investing possibilities in the constantly changing stock market might be likened to unearthing buried jewels. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023
RGLS stock results show that Regulus Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Gold Down Over 1%; ClearOne Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the S&P 500 index gaining over 1% on Tuesday. The Dow traded up 0.74% to 39,057.10 while the NASDAQ rose 1.41% to 16,245.83. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.